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Abstract: The toxicokinetics (TK) of hydrolyzed fumonisin B1 (HFB1) were evaluated in 16 broiler 
chickens after being fed either a control or a fumonisins-contaminated diet (10.8 mg fumonisin B1, 
3.3 mg B2 and 1.5 mg B3/kg feed) for two weeks, followed by a single oral (PO) or intravenous (IV) 
dose of 1.25 mg/kg bodyweight (BW) of HFB1. Fumonisin B1 (FB1), its partially hydrolyzed 
metabolites pHFB1a and pHFB1b, and fully hydrolyzed metabolite HFB1, were determined in chicken 
plasma using a validated ultra-performance liquid chromatography–tandem mass spectrometry 
method. None of the broiler chicken showed clinical symptoms of fumonisins (FBs) or HFB1 toxicity 
during the trial, nor was an aberration in body weight observed between the animals fed the FBs-
contaminated diet and those fed the control diet. HFB1 was shown to follow a two-compartmental 
pharmacokinetic model with first order elimination in broiler chickens after IV administration. 
Toxicokinetic parameters of HFB1 demonstrated a total body clearance of 16.39 L/kg·h and an 
intercompartmental flow of 8.34 L/kg·h. Low levels of FB1 and traces of pHFB1b were found in 
plasma of chickens fed the FBs-contaminated diet. Due to plasma concentrations being under the 
limit of quantification (LOQ) after oral administration of HFB1, no toxicokinetic modelling could be 
performed in broiler chickens after oral administration of HFB1. Moreover, no phase II metabolites, 
nor N-acyl-metabolites of HFB1 could be detected in this study. 
Keywords: mycotoxins; toxicokinetics; fumonisins metabolites; feeding trial; broiler chicken 
Key Contribution: For the first time toxicokinetic parameters of hydrolyzed fumonisin B1 (HFB1) 
were calculated in broiler chicken, after a feeding trial of a control or a fumonisin B1 contaminated 
diet and followed by a single oral or intravenous bolus of HFB1. 
 
1. Introduction 
Fumonisins (FBs) are secondary fungal metabolites of Fusarium verticillioides, F. proliferatum or 
other Fusarium species, that resemble each other structurally [1,2]. Fumonisin B1 (FB1), B2 (FB2) and B3 
(FB3) represent the most important of the more than 15 FBs analogues that have been described [3]. 
FBs can be divided into four main categories, namely A, B, C and P [4]. Since FB1 is the most prevalent 
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and toxic analogue, toxicological assessment of FBs has mostly been done for FB1. FB1 is a diester of 
propane-1,2,3-tricarboxylic acid (TCA), which has a long aminopolyol side-chain, namely 2-amino-
12,16-dimethyl-3,5,10,14,15-pentahydroxyeicosane [3]. FB2 and FB3 differ structurally from FB1 in the 
number and position of hydroxyl groups, since a free hydroxyl group is lacking on either the C-10 or 
the C-5 position, as shown in Figure 1 [2]. The primary amino group is known for the biological 
activity of FBs, as acetylation of FB1 to fumonisin A1 hampers the cytotoxicity as well as the inhibition 
of ceramide synthase [3]. 
 
Figure 1. Structures of the fumonisins FB1, FB2 and FB3 with tricarballylic acid side-chains (TCA), and 
of the hydrolyzed fumonisins HFB1 and HFB2 (or aminopentols, AP1 and AP2, respectively) and the 
corresponding N-acyl-derivatives [5]. Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
FBs reveal distinct structural similarities to sphingolipids, due to their long-chain base 
backbones. Hence, FBs have the ability to completely inhibit sphinganine N-acyl transferase 
(ceramide synthase), resulting in a disruption of the ceramide and sphingolipid metabolism [6–8]. 
Blockage of the ceramide synthase enzyme not only leads to the inhibition of sphingolipids synthesis, 
but also induces an accumulation of free sphinganine (Sa) and sphingosine (So) in tissues, serum and 
urine [2,4]. This associated increase of the Sa:So ratio, observed in tissues and body fluids after 
exposure to FBs, is a suitable biomarker of effect in animals and humans [2,9,10]. In most animal 
species, the liver, as well as the kidneys and the intestinal tract, are the main target organs of FBs 
toxicity [2,11,12]. Generally, poultry are rather resistant to FBs in comparison to mammals, especially 
pigs and horses [13–18]. Only during the first three days of life (≥ 125 mg/kg feed) was an increase in 
mortality after FB1 exposure observed in broiler chickens [13], as well as in growing ducks aged 12–
14 weeks (20 mg/kg feed) [16]. Feeding a FB1-contaminated diet (100–400 mg/kg feed) to broilers 
resulted in black, sticky diarrhea in the first 2 weeks of life [15]. Besides, broiler chickens fed an FBs-
contaminated diet in doses from 100 to 400 mg FB1/kg feed for 2 to 3 weeks showed a dose-dependent 
decrease in feed intake and bodyweight gain [13,15]. No negative effects on performance were 
observed under experimental conditions, at concentration levels which were below or approached 
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the European maximum guidance level in feed (20 mg FB1 + FB2/kg feed) [19]. However, it was 
recently demonstrated that even low to moderate dietary levels of FBs negatively affect enterocyte 
viability and proliferation, and the production of pro-inflammatory cytokines, and alter the intestinal 
barrier function, and therefore increase the susceptibility of avian species to important enteric 
infectious diseases, such as coccidiosis and necrotic enteritis [20–23]. Furthermore, the mRNA 
expression of genes encoding for the intestinal cytochrome P450 (CYP450), the drug-metabolizing 
enzyme CYP1A4, and the drug transporter mechanisms, such as multiple drug resistance protein 1 
(MDR1 or P-glycoprotein, P-gp), in broiler chickens were upregulated following exposure to 25 mg 
FB1 + FB2/kg feed for 15 days, which can affect the pharmacokinetic (PK) or toxicokinetic (TK) 
properties of other xenobiotics substrates [24]. 
Therefore, taking into account that mycotoxin contamination of feed is a continuous feed safety 
issue, resulting in economic losses during animal production [25], methods for the detoxification of 
feed have been developed. For FBs, these imply feed processing techniques, such as alkaline cooking 
(nixtamalization) used during the production of masa and tortillas for human consumption, and the 
application of mycotoxin binders/modifiers in animal feed. Mycotoxin binders, such as clays, are 
highly effective against aflatoxins, however, their detoxification capacity wit regards to FBs is rather 
limited. In contrast, following the application of FB esterase FumD (EC 3.1.1.87), enzymatic 
degradation results in conversion of FBs to the less toxic partially hydrolyzed FB1 (pHFB1), or fully 
hydrolyzed HFB1, by cleavage of the tricarballylic acid esters at the C-14 and/or C-15 position. FB 
esterase FumD is an enzyme of bacterial FB catabolism [26,27], which has recently been 
commercialized as FUMzyme® (BIOMIN GmbH, Getzersdorf, Austria) and authorized by the EU for 
usage in poultry and pigs. Enzymatic hydrolysis has been shown to be an effective detoxification 
method in broilers, since it prevents the FB-associated disruption of the sphingolipid metabolism, 
characterized by a reduced serum and hepatic Sa:So ratio and a counteracting FB-induced intestinal 
up-regulation of cytokine gene expression [interleukin-8 (IL-8) and IL-10] [28]. Besides, in accordance 
with different mammalian species [29–31], it has been demonstrated that the intestinal microbiota of 
broiler chickens and turkeys also has a limited capacity to hydrolyze FBs [28,32]. 
The only known metabolic pathway of FB1 is the hydrolyzation (hydrolysis) of its side-chains in 
vertebrates [11]. HFB1 is not only a 10-fold less potent inhibitor of ceramide synthase than FB1, but it 
is also a substrate for ceramide synthase in rat liver microsomes [5,26,31,33,34]. Acetylation of HFB1 
at the primary amino group, with fatty acids of variable chain lengths, results in the formation of N-
acyl-HFB1 (NAHFB1) metabolites, which are also known to be ceramide analogues. The in vivo 
formation of NAHFB1 has been demonstrated in rats [5]. Furthermore, phase II conjugation processes 
of FB1, e.g., sulphatation as proposed by Hopmans et al. (1997) [35], or glucuronidation, have not yet 
been identified. However, no data are available on the in vivo TK of HFB1, nor on the formation of 
NAHFB1 in chickens [36]. Furthermore, FB1 is not absorbed in vitro by human colon adenocarcinoma 
Caco-2 cells, also suggesting a low oral bioavailability. The oral bioavailability of FB1 in chickens is 
only 0.7% [36]. In contrast, for HFB1 a high transcellular passage has been observed in vitro, 
particularly from the basolateral to the apical side, suggesting that HFB1 is effluxed by P-gp [33,37]. 
Remarkably, this P-gp transport mechanism was upregulated following exposure to the toxic FBs 
parent molecules, which could affect the TK properties of the HFB1 metabolite, as it is a P-gp 
substrate. Since exposure to HFB1 is linked with the hydrolysis of FB1 by intestinal enzymes or by a 
feed additive enzyme, the aim of this study was to investigate not only the TK parameters of HFB1 
alone, but also the impact of prior exposure to FBs on these parameters. 
2. Results and Discussion 
During the animal experiment, no signs of illness due to FBs or HFB1 toxicity were observed in 
any of the broiler chickens. All birds were alert, showed a normal feed intake and normal droppings, 
and no regurgitation was observed. The average bodyweight (BW) was similar (p = 0.820) in both 
groups (control and FBs diet), 974 ± 109 and 1036 ± 110 g at day 21, respectively. This matched 
expectations, since the contaminated feed contained 10.8 mg FB1, 3.3 mg FB2 and 1.5 mg FB3/kg feed, 
and therefore approached, but was below, the EU guidance level of 20 mg FB1 + FB2/kg [19]. 
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Additionally, HFB1 is generally known to be less toxic than its parent toxin FB1 [26,27], and poultry 
species are known to be able to tolerate high doses of FB1, especially regarding performance response, 
with no effect on growth of broiler chickens up to 75–100 mg FB1/kg feed [15]. 
To the authors’ knowledge, for the first time, the TK properties of HFB1 were determined in 
broiler chickens, both after feeding a control and FBs-contaminated diet. In pigs, biotransformation 
of FB1 into pHFB1, and further to HFB1, by their digestive microbiota and liver has been observed 
after being fed an FBs-contaminated diet containing 45 mg FB1, 8.6 mg FB2 and 4.6 mg FB3/kg for 10 
days, together with a persistence of low levels of pHFB1 in most organs for several days [30]. 
However, only low concentrations of pHFB1a and pHFB1b have been detected in the plasma of broiler 
chickens, fed an FBs-contaminated diet with 10 mg FBs/kg for 14 days [28]. The formation of pHFB1a, 
pHFb1b and HFB1 after FB1 exposure has been described in turkeys [32], monkeys [29] and rats [31] as 
well. Accordingly, in this study, only traces (> limit of quantification; LOQ) of pHFB1b (0.94–1.34 
ng/mL and 0.93–2.43 ng/mL, respectively) were detected in a few samples of broiler chickens fed the 
FBs-contaminated diet, and subsequently administered an IV or PO bolus of HFB1, respectively. 
Although, the presence of pHFB1a was detected in some samples of broilers fed the FBs-contaminated 
diet (> limit of detection; LOD), it could not be quantified (<LOQ). No pHFB1a or pHFB1b was detected 
in chickens fed the control diet. Low levels of FB1 were observed in chickens fed the FBs-contaminated 
diet, with average background levels at all timepoints of 4.89 ± 5.91 ng/mL and 2.67 ± 3.70 ng/mL, in 
broiler chickens administered HFB1 IV and PO, respectively. No FB1 was detected in the plasma of 
animals fed the control diet. Consequently, it can be concluded that the observed pHFB1 in the plasma 
of animals fed the FBs-contaminated diet resulted from hydrolysis of the FB1 present in the diet. 
However, the intestinal microbiota of broiler chickens and turkeys seems to have a rather limited 
capacity to hydrolyze FBs [28,32]. HFB1 initiated lesser inflammatory responses than FB1 in an in vitro 
co-culture model of porcine intestinal epithelial and immune cells [38]. In vivo toxicity of the 
intermediate, pHFB1, has only been investigated in rats so far, resulting in no observed in vivo toxicity 
[31]. On the other hand, hepatic and renal lesions, in terms of single-cell necrosis, mitosis, apparent 
collapse of the centrilobular parenchyma of the liver and single-cell necrosis of the outer medulla, 
and cytoplasmic vacuolation of the kidney, have been reported in rats fed nixtamalized feed 
containing HFB1 [39], while no hepatotoxicity or pathological changes of the liver, brain, heart, 
kidneys, thymus or mesenteric lymph nodes examined in mice fed purified HFB1 have been detected 
[40]. This different outcome could probably be explained by the presence of residual, partially 
hydrolyzed or masked FB1, following the process of nixtamalization [5]. However, no significant 
influence of HFB1 on the intestinal lesion score of the villi morphology in piglets exposed to HFB1 has 
been observed [41]. 
No N-acyl or phase II metabolites of HFB1 were detected in any of the samples in this study. N-
acyl-metabolites of HFB1 were highly cytotoxic in human colonic HT29 cells, and were also 
characterized as a potent inhibitor of ceramide synthase [34]. HFB1 acylation has been evaluated in 
rats, and although N-acyl-metabolites were detected, no toxicity was observed in vivo [5]. While N-
acylation of FB1 and HFB1 occurred in human cell lines and in rats [33,34], the occurrence of these 
metabolites in avian species has not yet been observed, matching the absence of these metabolites in 
this study. 
Comparative HFB1 plasma concentration–time profiles, following IV HFB1 administration to 
broiler chickens fed either a control diet or a FBs-contaminated diet, are shown in Figure 2. Visual 
inspection of the goodness-of-fit plots of the individual, model-predicted concentrations (IPRED) 
versus the observed HFB1 plasma concentrations (Cobs) revealed an appropriate structural model for 
most individuals (Figure S1A). The QQ-plots of the conditionally weighted residuals of Cobs 
demonstrated the normal distribution of the weighted residuals (Figure S1B). The addition of the 
covariate experimental diet (control versus FBs-contaminated) did not significantly improve the -2 
log likelihood-ratio (2LL) of any of the fixed effect parameters’ volume of distribution of the central 
compartment (Vc), volume of distribution of the peripheral compartment (Vp), total body clearance 
(Cl), or intercompartmental flow (Q), and was therefore not retained in the final model. 
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Figure 2. Comparative plasma concentration−time profile of HFB1 after intravenous (IV) 
administration of 1.25 mg HFB1/kg bodyweight to broiler chickens fed either a control diet (n = 8) or 
a fumonisins (FBs)-contaminated diet (10.8 mg FB1, 3.3 mg FB2 and 1.5 mg FB3/kg feed, n = 8) for two 
weeks. Values are presented as mean + standard deviation (SD). 
The toxicokinetic parameters of HFB1 following IV administration are shown in Table 1, and are 
described by a two-compartment model. The mean plasma concentration of HFB1 in broiler chickens 
fed an FBs-contaminated diet for 2 weeks following IV administration (plasma concentration at time 
0; C0) was 339.59 ng/mL. The total exposure of HFB1 in broiler chickens after IV administration, from 
timepoint 0 to infinity (area under the plasma-concentration time curve from time 0 to infinity; AUC0-
inf), was 76.26 ng·h/mL. Regarding volume of distribution (Vd), values of 3.68 L/kg and 5.04 L/kg have 
been determined for the central and peripheral compartments, respectively, thus resulting in a Vd of 
8.7 L/kg at steady state (Vss). Accordingly, pigs given a single HFB1 IV bolus showed a Vd of 11.0 
L/kg, in a one-compartmental model [42]. Furthermore, a short distribution half-life (T1/2ɑ) of 0.09 h, 
followed by a longer elimination half-life (T1/2β) of 0.69 h, was revealed. In barrows given a single IV 
bolus, of 0.056 mg/kg BW, of HFB1, a T1/2ɑ of 0.05 h and a T1/2β of 1.01 ± 0.80 h was observed [42]. The 
mean residence time (MRT) of HFB1 after IV administration to broiler chickens was 0.53 h, and the 
elimination rate constant (ke) was 4.4 h–1. In comparison to pigs, with a total body clearance of 6.7 
L·kg/h in barrows after IV HFB1 administration, broilers seem to have a higher total body clearance 
(16.39 L/kg·h). The latter could concur with the oral bioavailability of parental FB1 being higher in 
swine than in poultry, with values of 3.1% [42] and 0.7% [36], respectively, and with poultry being 
rather resistant to FBs toxicity when compared to pigs or other mammals [13–18].  
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Table 1. Population toxicokinetic results of intravenous (IV) administration of HFB1 (1.25 mg/kg BW) 
to broiler chickens [n = 16, 8 animals fed a control diet and 8 animals fed a fumonisins (FBs)-
contaminated diet prior HFB1 administration]. 
Θ Tvθ CV (%) ω 
Vc (L/kg) 3.68 23.47 0.095 
Vp (L/kg) 5.04 41.47 0.009 
VSS (L/kg) 8.72 28.75 / 
Cl (L/kg·h) 16.39 12.67 0.126 
Q (L/kg·h) 8.34 41.37 0.391 
AUC0-inf (ng·h/mL) 76.26 12.67 / 
C0 (ng/mL) 339.59 23.47 / 
Ke (1/h) 4.45 26.27 / 
MRT (h) 0.53 31.56 / 
T1/2α (h) 0.09 33.26 / 
T1/2β (h) 0.69 40.41 / 
Θ: fixed effect parameter; Tvθ: population typical value of the fixed effect parameter; CV: coefficient 
of variation; ω: variance of the interindividual variability (only for fixed parameters). Addition of the 
covariate experimental diet (control versus FBs-contaminated) did not significantly improve the –2 
log likelihood (–2LL) of any of the fixed effect parameters, and was therefore not retained in the final 
model. Vc: volume of distribution of the central compartment; Vp: volume of distribution of the 
peripheral compartment; Vss: volume of distribution at steady state; Cl: total body clearance; Q: 
intercompartmental flow, AUC0-inf: area under the plasma concentration–time curve from time 0 to 
infinity; C0: plasma concentration at time 0 following IV administration; Ke: elimination rate constant; 
MRT: mean residence time; T1/2α: distribution half-life, and T1/2β: elimination half-life. 
Plasma concentrations of HFB1 after oral administration were only above the LOQ in a limited 
number of samples, and are shown in Figure 3. Consequently, no TK modelling could be performed 
on these data. Still, the rather fast appearance of HFB1 in the systemic circulation after oral 
administration indicates that the ingested mycotoxin is mainly absorbed in the proximal part of the 
small intestines. 
 
Figure 3. Comparative plasma concentration−time profiles of HFB1 after oral (PO) administration of 
1.25 mg HFB1/kg bodyweight to broiler chickens fed either a control diet (n = 8) or a fumonisins (FBs)-
contaminated diet (10.8 mg FB1, 3.3 mg FB2 and 1.5 mg FB3/kg feed, n = 8) for two weeks. Values are 
presented as means + standard deviatie (SD). 
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The Tmax of HFB1 (10 min) after oral HFB1 administration in the FBs-fed group was reached 
remarkably fast, when compared to studies of oral FB1 intake in laying hens, turkeys and ducks, 
where respective Tmax values of 60 min, 180 min and 60–120 min were observed [43]. 
Previously, a disturbance of intestinal homeostasis of chickens fed an FBs-contaminated diet 
(18.6 mg FB1 + FB2/kg feed) was demonstrated [21]. In another study, broiler chickens were either fed 
an FBs-contaminated (8.70 mg FB1/kg, 4.15 mg FB2/ kg and 1.44 mg FB3/kg feed) or a control diet, 
resulting in FB1 influencing the expression of intestinal P-gp [24]. With HFB1 being a substrate of this 
receptor [24], another aim of this research was to examine whether prolonged FB1 exposure would 
influence the uptake of its metabolite HFB1 in the intestines of broiler chickens. Regarding the 
difference in plasma concentrations between the FBs and the control diet fed groups, after oral 
administration of HFB1, in this study, one could presume that a prolonged FBs exposure actually does 
influence the intestinal uptake of HFB1. But as mentioned before, the quantity of plasma concentration 
measurements above the LOQ, after oral HFB1 administration, was insufficient to allow the drawing 
of conclusions from those results. The latter is also held responsible for the fact that no calculation of 
oral bioavailability of HFB1 could be made. Nevertheless, a high transcellular passage, particularly 
from the basolateral to the apical side, was revealed for HFB1 in human colon adenocarcinoma Caco-
2 cells, suggesting that HFB1 is effluxed by P-gp [33,37]. Since an increased expression of multi-drug 
resistance protein 1 (MDR1), encoding for P-gp, could be observed in the intestine of broiler chickens 
fed an FBs-contaminated diet [24], oral bioavailability of HFB1 could vary, leaving one with the need 
for more research on the oral bioavailability of HFB1 in avian species. In broiler chickens, the oral 
bioavailability of FB1, being mainly negatively charged in the duodenum and jejunum due to the pH 
which therefore limits oral absorption by passive non-ionic transcellular diffusion [43], is known to 
be rather low [44]. Similarly, in this study only very low plasma levels of HFB1 were detected in 
broiler chickens following oral administration, suggesting a very low oral bioavailability. That said, 
in rats, the bioavailability of HFB1 was thought to be greater than that of FB1, since about 2.5-fold 
greater amounts of 14C-HFB1, compared to 14C-FB1, were excreted in urine after oral administration of 
0.69 µmol 14C-FB1 and 14C-hydrolyzed FB1/kg BW [45], increasing the likelihood that HFB1 can be 
absorbed by the gut, and in the meantime allowing the subsequent metabolism of N-acyl-HFB1 and 
the enhancing of its possible toxicological effects. 
3. Conclusions 
While HFB1 is shown to be less toxic than its parental toxin FB1, its toxicokinetic pathways in 
avian species are still widely unexplored. In this study, toxicokinetic parameters following 
administration of a single IV bolus of HFB1 to broiler chickens have been determined (Vc, Vp, Vss, Cl, 
Q, AUC0-inf, C0, ke, MRT, T1/2α and T1/2β). The plasma concentrations of HFB1 after oral administration 
were only above the LOQ in a limited number of samples. Consequently, no TK modelling could be 
performed on these data. Traces of pHFB1b (0.94–1.34 ng/mL and 0.93–2.43 ng/mL, respectively) have 
been detected in a few samples of broiler chickens fed the FBs-contaminated diet, and subsequently 
administered an IV bolus or PO bolus of HFB1, respectively. Using UPLC-HRMS, no phase II 
metabolites or N-acyl metabolites of HFB1 could be detected in any of the samples. 
4. Materials and Methods 
4.1. HFB1 for Animal Trial 
HFB1 for oral (PO) and intravenous (IV) administration was prepared as previously described 
[31] with some minor changes. HFB1 for PO administration was obtained by enzymatic treatment of 
F. verticillioides culture material with the FB carboxylesterase FumD (80 U enzyme/g culture material) 
for 30 min, and subsequently purified and lyophilized [31]. Per 250 g of culture material, 2550 µmol 
HFB1 was obtained. 
HFB1 for IV administration was prepared by alkaline hydrolysis of FB1 analytical standard 
(Biopure, Tulln, Austria). Therefore, 5 mL of FB1 solution (7.4 mg/mL water) was hydrolyzed with 4 
mL of 2.5M NaOH by shaking for 7.5 h. After completing the conversion, the formed HFB1 was 
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recovered by liquid–liquid extraction (eight times with acetonitrile (ACN)). The achieved HFB1 
solution was purified over an SPE C18 column to remove salts and tricarballylic acids, and 
subsequently diluted in a 0.9% NaCl solution up to a concentration of 4.18 mg HFB1/mL, with traces 
of pHFB1a (0.0045 mg/mL). HFB1 for PO and IV administration was stored at 2–8 °C. 
4.2. Feed Preparation and Experimental Diets 
A commercial broiler starter diet was fed to all chickens (Vanden Avenne, Ooigem, Belgium) 
during the first week of the experiment. Later, this diet is referred to as control diet. From day 8 until 
day 24 chickens were fed either the control diet without mycotoxins [commercial broiler grower diet 
(Vanden Avenne)], or a grower diet experimentally contaminated with FBs. None of the diets 
contained a mycotoxin detoxifier. Screening of the control starter and grower feeds for mycotoxin 
contamination was executed by a liquid chromatography tandem mass spectrometer (LC-MS/MS) 
method, as described by Monbaliu et al. [46]. The levels of all tested mycotoxins were below the 
decision limit (CCα) in the control starter and grower diets. More specifically, the CCα values of FB1, 
FB2 and FB3 were 58, 45 and 42 µg/kg feed, respectively. 
To produce the grower diet experimentally contaminated with FBs, FBs culture material was 
mixed with 500 g of control feed. Lyophilized FBs culture material of F. verticillioides (M-3125) [47] 
(7.37 g FB1/g and 2.93 g FB2/g) was obtained from Biopure, Romer Labs Diagnostic GmbH (Tulln, 
Austria) and stored at 2–8 °C. This premix was then blended with 5 kg of control feed to ensure a 
homogeneous distribution of the mycotoxins. The premix was blended for 20 min into the total 
quantity of feed necessary for the trial. To test the homogeneity of FBs in feed, samples were taken at 
three different points in the batch and analyzed for FBs as described for the control diets. The FBs-
contaminated diet contained 10.8 mg FB1, 3.3 mg FB2 and 1.5 mg FB3/kg feed. 
4.3. Animal Experiment 
A total of 16 one-day-old broiler chickens (Ross 308) were obtained from a commercial hatchery 
(Vervaeke-Belavi, Tielt, Belgium), and were fed a starter diet without mycotoxins during the first 
week. Subsequently, animals were randomly divided into two experimental groups of eight animals 
(4 male/4 female). While one group was being fed a control grower diet from day 8 onwards, the 
other group was given a FBs-contaminated grower diet. An 18 h/6 h light/darkness program was 
applied. Feed and drinking water were provided ad libitum. 
A toxicokinetic (TK) study of HFB1 was performed following a two-way cross-over design. Each 
broiler chicken was administered a bolus of HFB1 (1.25 mg/kg bodyweight) either orally (PO) or 
intravenously (IV) (vena cutanea ulnaris superficialis or wing vein). At day 21, four chickens of each 
group were administered HFB1 IV, and the four other animals received HFB1 PO. After a wash out 
and recovery period of two days, the protocol was repeated at day 24 in a cross-over design. Animals 
were feed-deprived overnight (8 h) prior to, and until 3 h after, HFB1 administration. After each bolus 
dosing, blood was collected into heparinized tubes by direct venipuncture of the leg vein (vena 
metatarsalis plantaris superficialis) before (0 h) and at different time points after HFB1 administration: 
5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h and 9 h post-administration 
(p.a.). Blood samples were centrifuged (2851× g, 10 min, 4 °C) and plasma was stored at ≤–15 °C until 
analysis. 
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and the Faculty of Bioscience Engineering of Ghent University (EC 2015/10, approval date: 
9 March 2015). 
4.4. Plasma Fumonisins Analysis: FB1, FB2, FB3, HFB1, pHFB1a, pHFB1b, Phase II Metabolites and N-Acyl 
Metabolites 
FB1, and its partially hydrolyzed metabolites pHFB1a + b and hydrolyzed metabolite HFB1, in 
plasma, were determined using a validated sensitive and specific UPLC-MS/MS method as described 
by De Baere et al. (2018) [48]. 
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4.4.1. Preparation of Standard Solutions 
Stock solutions of FB1, FB2 and FB3 (1 mg/mL) were made in water/ACN (50/50, v/v) and kept at 
2–8 °C. Working solutions of 10 µg/mL, 1 µg/mL and 0.1 µg/mL were made by adequate dilution of 
the stock solution in water/ACN (50/50, v/v). The standard mixture solution contained FB1, HFB1, 
pHFB1a and pHFB1b and was adequately diluted in water/ACN (50/50, v/v) in order to prepare 
working solutions necessary for the preparation of calibrator and quality control (QC) samples. A 
working solution of 1 µg/mL of 13C34-FB1 was made in water/ACN (50/50, v/v) to obtain the internal 
standard (IS). All working solutions were kept at 2–8 °C. 
4.4.2. Plasma Sample Pre-Treatment 
To 100 µL of plasma 12.5 µL of the IS working solution (1 µg/mL) was added. Then, after vortex 
mixing the sample was transfered onto an OstroTM 96-well plate. Next, 300 µL of 1% formic acid (FA) 
in ACN was added, after which the sample was aspirated 3 times in order to stimulate protein 
precipitation. By the application of a vacuum (67.7 kPa) for 10 min, the sample was run through the 
96-well plate. An aliquot of 2.5-µL was injected onto the LC-MS/MS instrument. 
4.4.3. UPLC-MS/MS Method for Quantification 
Briefly, the LC system was composed of an Acquity UPLC H-Class Quaternary Solvent Manager 
and Flow-Through-Needle Sample Manager with temperature-controlled tray and column oven 
from Waters (Zellik, Belgium). Chromatographic separation was accomplished on an Acquity UPLC 
HSS T3 column (100 mm × 2.1 mm i.d., dp: 1.8 µm) (Waters, Zellik, Belgium) combined with an 
Acquity HSS T3 1.8 µm Vanguard pre-column (Waters, Zellik, Belgium). The mobile phase A was 
composed of 0.3% FA and 10 mM NH4FA in water, and the mobile phase B was ACN. A gradient 
elution of 0–0.5 min (90% A, 10% B), 5.5 min (linear gradient to 90% B), 5.5–7.5 min (10% A, 90% B), 
7.7 min (linear gradient to 90% A) and 7.7–10.0 min (90% A, 10% B) was performed. The flow-rate 
was set at 0.4 mL/min. The temperatures of the column oven and autosampler tray were adjusted to 
40 °C and 8 °C, respectively. The UPLC column effluent was coupled to a Xevo TQ-S® MS/MS system, 
supplied with a positive electrospray ionization (ESI) probe (all from Waters). A divert valve was 
utilized and the UPLC effluent was routed to the mass spectrometer from 2.5 to 4.5 min. Optimization 
of instrument parameters was obtained by directly infusing working solutions of 1 µg/mL of FB1, FB2, 
FB3, the IS and a diluted standard mixture solution, which contained FB1, HFB1, pHFB1a and pHFB1b 
at concentrations of 0.5, 0.86, 1.43 and 2.5 µg/mL, respectively, combined with the mobile phase (50% 
A, 50% B, flow-rate: 200 µL/min). The flow-rate was set at 10 µL/min. MS/MS acquisition was 
operated in the multiple reaction monitoring (MRM) mode [48]. 
4.4.4. UPLC-HR-MS Analysis for Identification 
To determine potential HFB1 phase II and N-acyl metabolites in plasma samples of broiler 
chickens, an Acquity I-Class UPLC interfaced to a Synapt G2-Si HDMS instrument (Waters, Zellik, 
Belgium) was used [48]. 
4.5. Toxicokinetic Modelling 
Plasma concentration–time data were analyzed with a nonlinear mixed-effects modelling 
approach using quasi-random parametric expectation maximization (QRPEM) as an estimation 
method in Phoenix NLME® (Certara, Cary, NC, USA). The structural toxicokinetic model for the IV 
data was a two-compartmental model with first order elimination as shown in Equation 1. 
(dA1/dt) × 1/Vc = –Cl × C – Q × (C – C2) 
(dA2/dt) × 1/Vp = Q × (C – C2) 
(1) 
Where dA1/dt is the rate of the decrease of the amount of mycotoxin in the plasma or central 
compartment, dA2/dt is the rate of decrease of the amount of mycotoxin in the peripheral 
compartment, Vc is the volume of distribution of the central compartment, Vp is the volume of 
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distribution of the peripheral compartment, Cl is total body clearance, Q is the intercompartmental 
flow and C and C2 are the concentrations of the toxin in the central and peripheral compartments, 
respectively. 
Interindividual variability was expressed using an exponential error model according to 
Equation 2: 
Pi = θP × eηPi (2) 
where Pi is the parameter in the ith bird, θP is the typical value of the parameter in the population, and 
ηPi is a random variable in the ith bird, with a mean of zero and a variance of ω². Interindividual 
variability is reported as ω. Residual variability (ε), with a mean of zero and a variance of σ², was best 
described with a multiplicative error model in Equation 3. 
Cobs = Cpred × (1 + ε) (3) 
where Cobs is the observed concentration for the individual and Cpred is the model-predicted 
concentration plus the error value (ε). 
Structural and error model selection was guided by visual inspection of goodness-of-fit plots 
(e.g., observed vs predicted plasma concentrations, weighted residuals versus predicted 
concentrations, and weighted residuals versus time), –2LL, Akaike information criterion (AIC) and 
Bayesian information criterion (BIC) as well as precision of the parameter estimates. The models were 
chosen based on the smaller values of –2LL, AIC and BIC, the better precision of estimates, and the 
superior goodness-of-fit plots. 
The evaluated covariate was the prior feeding with FBs-contaminated feed versus feeding with 
uncontaminated control feed (categorical variable). A stepwise forward–backward process was used 
to evaluate whether inclusion of the covariates significantly improved the model fit using a –2LL test. 
A decrease in –2LL with a p-value < 0.01 was considered significant for addition, and p < 0.001 for 
exclusion, of the covariate. 
The following fixed effect parameters were determined: Vc, Vp, Cl and Q. The computed 
secondary parameters were: C0, AUC0-inf, Ke, MRT, T1/2α and T1/2β. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/6/413/s1,  
Figure S1: Visual evaluation of the population model of HFB1 after intravenous (IV) dosing: scatter plot of the 
population dependent variable (DV), namely observed plasma concentration (Cobs), versus the individually 
predicted plasma concentration values (IPRED) (A) and QQ plot of the conditionally weighted residuals of Cobs (B). 
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